Update From the Advisory Committee on Immunization Practices

2019 ◽  
Vol 8 (5) ◽  
pp. 379-383 ◽  
Author(s):  
Sean T O’Leary ◽  
Yvonne A Maldonado ◽  
David W Kimberlin
Keyword(s):  
Advisory Committee ◽  
Safety Data ◽  
Pneumococcal Vaccination ◽  
The United States ◽  
Human Papillomavirus Vaccine ◽  
Vaccine Preventable Diseases ◽  
Japanese Encephalitis Vaccine ◽  
Control And Prevention ◽  
Clinical Trial Results ◽  
Papillomavirus Vaccine

Abstract The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. The group usually has 15 voting members, each of whom is appointed to a 4-year term. ACIP members and Centers for Disease Control and Prevention staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and clinical trial results. Representatives from the American Academy of Pediatrics (Y. A. M. and D. W. K.) and the Pediatric Infectious Diseases Society (S. T. O.) are present as liaisons to the ACIP. The ACIP met February 27 to 28, 2019, to discuss hepatitis A (HepA) vaccination of human immunodeficiency virus–infected persons, pneumococcal vaccination among adults aged 65 years or older, influenza vaccine effectiveness and safety, anthrax vaccination in the setting of a mass exposure, human papillomavirus vaccine, zoster vaccines, and Japanese encephalitis vaccine.

Update From the Advisory Committee on Immunization Practices

2019 ◽  
Vol 8 (6) ◽  
pp. 495-500
Author(s):  
Sean T O’leary ◽  
Yvonne A Maldonado ◽  
David W Kimberlin
Keyword(s):  
Advisory Committee ◽  
Hepatitis A Virus ◽  
Safety Data ◽  
The United States ◽  
Vaccine Research ◽  
Vaccine Preventable Diseases ◽  
American Academy Of Pediatrics ◽  
Control And Prevention ◽  
Clinical Trial Results ◽  
Health Experts

Abstract The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. There usually are 15 voting members, but at the June 2019 meeting, only 14 were present; each member’s term is 4 years. ACIP members and Centers for Disease Control and Prevention (CDC) staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and clinical trial results. Representatives from the American Academy of Pediatrics (AAP) (Y. A. M. and D. W. K.) and the Pediatric Infectious Diseases Society (S. T. O.) are present as liaisons to the ACIP. The ACIP met on June 26 to 27, 2019, to discuss the use of human papillomavirus (HPV) vaccine in adults, pneumococcal vaccines in adults, measles updates, zoster vaccine, influenza vaccines, hepatitis A virus (HAV) vaccines, meningococcal vaccines, and dengue vaccine.

scholarly journals Update from the Advisory Committee on Immunization Practices

2020 ◽  
Vol 9 (1) ◽  
pp. 3-5
Author(s):  
Sean T O’Leary ◽  
Yvonne A Maldonado ◽  
David W Kimberlin
Keyword(s):  
Advisory Committee ◽  
Safety Data ◽  
Vaccine Safety ◽  
The United States ◽  
Vaccine Research ◽  
Vaccine Preventable Diseases ◽  
American Academy Of Pediatrics ◽  
Control And Prevention ◽  
Adult Immunization ◽  
Health Experts

Abstract The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. There are usually 15 voting members; members’ terms are for 4 years. ACIP members and Centers for Disease Control and Prevention staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and results from clinical trials. Representatives from the American Academy of Pediatrics (Y. A. M., D. W. K.) and the Pediatric Infectious Diseases Society (S. T. O.) are present as liaisons to the ACIP. The ACIP met on 23–24 October 2019 to discuss pertussis vaccines, the child/adolescent and adult immunization schedule, influenza vaccine effectiveness and safety, Ebola vaccine, orthopoxvirus vaccines, Dengue vaccine, rabies vaccine, measles, and vaccine safety update.

scholarly journals Human papillomavirus vaccine initiation among 9–13-year-olds in the United States

2015 ◽  
Vol 2 ◽  
pp. 892-898 ◽  
Author(s):  
Kelly L. Donahue ◽  
Kristin S. Hendrix ◽  
Lynne A. Sturm ◽  
Gregory D. Zimet
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
The United States ◽  
Human Papillomavirus Vaccine ◽  
Vaccine Initiation ◽  
Papillomavirus Vaccine

scholarly journals 962. Trends in Cervical Pre-cancers by Race and Ethnicity During the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008–2016

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S29-S29
Author(s):  
Julia Gargano ◽  
Rayleen Lewis ◽  
Hillary Hunt ◽  
Nancy McClung ◽  
Nancy M Bennett ◽  
...  
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
The United States ◽  
Adenocarcinoma In Situ ◽  
Human Papillomavirus Vaccine ◽  
Impact Monitoring ◽  
Vaccine Impact ◽  
Race Ethnicity ◽  
Papillomavirus Vaccine

Abstract Background Since human papillomavirus (HPV) vaccine introduction in the United States in 2006, cervical pre-cancer incidence has declined in young women, but pre-cancer trends have not been reported by race/ethnicity. We evaluated trends in cervical pre-cancers from 2008 to 2016 in non-Hispanic (NH) white, NH black, NH Asian, and Hispanic women identified through active population-based surveillance in the 5-site Human Papillomavirus Vaccine Impact Monitoring Project (HPV-IMPACT). Methods We analyzed data on cervical intraepithelial neoplasia (CIN) grades 2–3 and adenocarcinoma in situ (CIN2+) cases aged 20–39 years. Annual CIN2+ rates per 100,000 women were calculated stratified by race/ethnicity in 5-year age groups, using multiple imputation to account for 10% missing race/ethnicity data. Rates were also calculated using estimated numbers screened for cervical cancer to control for known declines in screening. Trends, evaluated using JoinPoint software, are presented as average annual percentage changes (AAPC) with 95% confidence intervals (CI). Results A total of 18,222 CIN2+ cases (62% NH white, 16% NH black, 16% Hispanic, 6% Asian) were reported from 2008 to 2016. CIN2+ rates among 20–24 year-olds declined significantly in all groups: NH white, AAPC: −14.2 (95% CI: −16.3, −12.1); NH black, AAPC: −15.5 (−19.5, −11.4); Asian, AAPC: −14.8 (−20.5, −8.8); Hispanic, AAPC: −14.3 (−17.9, −10.5). In 25–29 year olds, a significant decline was observed for NH whites only (AAPC: −2.4, [−4.0, −0.8]). No declines were seen in 30–34 or 35–39 year olds. Among screened 20–24 year-olds, significant but smaller declines were observed (AAPC: −9.8 to −8.4); no declines were observed in screened 25–29 year olds or older groups. Conclusion In this evaluation of CIN2+ trends by race/ethnicity during the HPV vaccine era, the significant declines in 20–24 year olds across all groups, including among screened women, is consistent with equitable vaccine impact on CIN2+. Disclosures All Authors: No reported Disclosures.

“What shots do I need?”

HIV ◽  
2020 ◽  
pp. 253-258
Author(s):  
Giorgos Hadjivassiliou ◽  
Edgar T. Overton
Keyword(s):  
Varicella Vaccine ◽  
The United States ◽  
Human Papilloma Virus Vaccine ◽  
Vaccine Preventable Diseases ◽  
Cell Counts ◽  
Cd4 Cell Counts ◽  
Persons Living With Hiv ◽  
Control And Prevention ◽  
Living With Hiv ◽  
Cd4 Cell

This chapter reviews the current recommendations for adult persons living with HIV (PLWH) in the United States regarding vaccine-preventable diseases. In clinical practice, PLWH should be offered annual influenza vaccine; a combination of tetanus, diphtheria, and pertussis vaccine; depending on previous vaccination, pneumococcal vaccine, meningococcal conjugate vaccine, and hepatitis A and hepatitis B vaccines. Human papilloma virus vaccine can be given in PLWH up until the age of 26. Live vaccines, including the measles-mumps-rubella vaccine and varicella vaccine, can be given in those individuals who have CD4 cell counts of greater than 200 cells/mm3 and did not receive these vaccines during childhood. Some expert panels endorse recombinant zoster vaccination in PLWH at least 50 years old, although there is no current official recommendation from the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. The chapter covers routine vaccinations for PLWH.

scholarly journals Early Policy Responses to the Human Papillomavirus Vaccine in the United States, 2006–2010

2014 ◽  
Vol 55 (5) ◽  
pp. 659-664 ◽  
Author(s):  
Miriam J. Laugesen ◽  
Ritesh Mistry ◽  
Kelley A. Carameli ◽  
Kurt M. Ribisl ◽  
Jack Needleman ◽  
...  
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
The United States ◽  
Human Papillomavirus Vaccine ◽  
Policy Responses ◽  
Papillomavirus Vaccine

scholarly journals Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States

Cancer ◽  
2015 ◽  
Vol 121 (16) ◽  
pp. 2775-2781 ◽  
Author(s):  
Susan Hariri ◽  
Michelle L. Johnson ◽  
Nancy M. Bennett ◽  
Heidi M. Bauer ◽  
Ina U. Park ◽  
...  
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
The United States ◽  
Population Based ◽  
High Grade ◽  
Human Papillomavirus Vaccine ◽  
Cervical Lesions ◽  
Papillomavirus Vaccine ◽  
Early Human
Sign in / Sign up

Export Citation Format

Share Document